Date: 18-Sep-2020

Dr. Reddys Laboratories Announces Settlement Of U.S. Revlimid® (lenalidomide) Capsules Patent Litigation With Celgene, A Bristol Myers Squibb Company

India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy's Laboratories, Inc.  (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide) Capsules.

In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr. Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022 subject to regulatory approval. The agreed-upon percentages are confidential. Dr. Reddy’s is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.

“We are pleased with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market soon subject to regulatory approval for the benefit of patients,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories.

Revlimid® is a trademark of Celgene, a wholly owned subsidiary of Bristol Myers Squibb. Please refer to Revlimid® Package Insert for Black Box warning and important safety information.

RDY-0920-318

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe